United States securities and exchange commission logo




                                                                                
                          June 26, 2024

       John Friend
       Chief Executive Officer
       Kazia Therapeutics Limited
       Three International Towers Level 24
       300 Barangaroo Avenue
       Sydney, NSW, 2000, Australia

                                                        Re: Kazia Therapeutics 
Limited
                                                            Registration 
Statement on Form F-1
                                                            Filed June 25, 2024
                                                            File No. 333-280447

       Dear John Friend:

              This is to advise you that we have not reviewed and will not 
review your registration
       statement.

               Please refer to Rules 460 and 461 regarding requests for 
acceleration. We remind you
       that the company and its management are responsible for the accuracy and 
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of 
action by the staff.

                                                        Please contact Tim 
Buchmiller at 202-551-3635 with any questions.



                                                                                
                          Sincerely,

                                                                                
                          Division of Corporation Finance
                                                                                
                          Office of Life Sciences
       cc:                                              Finnbarr D. Murphy, 
Esq.